SELLAS Life Sciences Group, Inc. — Director's Dealing 2017

Jan 19, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Galena Biopharma, Inc. (GALE)
CIK: 0001390478
Period of Report: 2017-01-17

Reporting Person: Knapp Thomas J (General Counsel)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2017-01-17	Stock Option (right to buy)	$1.81	A	5000	Acquired	2027-01-17	Common Stock (5000)	Direct

Footnotes

F1: Granted pursuant to the Issuer's 2016 Incentive Plan.

F2: This stock option will vest in 16 equal, quarterly installments over four years beginning three months from the date of grant, so long as the Reporting Person remains in the company's continuous employ through the vesting period.